11 results
2.5 Study rationaleThe nephrotoxicity caused by cisplatin is of great concern both in that it is dose-limiting and can be detrimental to the patient. Much work has been done to reduce or prevent this damage to renal cells, however to date the best…
To test the impact of the addition of axitinib to standard chemotherapy treatment on histology samples
The primary safety objective of this investigation is to assess the safety of long-term LES electrical stimulation therapy in patients with GERD.The primary functionality objective of this study is to evaluate the ability of the device to initiate…
1. Define risk profiles based on retrospective data in a cohort of bipolar patients. These profiles will be based on the effects of various combinations of MR and GR genotypes involved in stress regulation on symptoms, course of the illness and…
Primary objectivesTo compare overall survival for MK-7684A in combination with the background therapy of etoposide/platinum followed by MK-7684A to atezolizumab in combination with the background therapy of etoposide/platinum followed by…
To evaluate the safety and efficacy of long term stimulation of the lower esophageal sphincter in patients with gastroesophageal reflux disease after sleeve gastrectomy.
The aim of this study is to evaluate the efficacy of a personalized drug profiling method using short-term cultures of malignant cells derived from the patient*s pleural fluid.
Primary: to characterize the safety and tolerability of GSK3052230 in combination with chemotherapy regimens, to determine the MTD and to assess overall response rate in patients with stage IV or recurrent squamous NSCLC with FGFR1 gene…
Primary objective:To compare the Progression Free Survival (PFS) per RECIST 1.1 as assessed by blinded independent central radiologists* review in subjects with PD-L1 strong, 1L metastatic NSCLC treated with MK-3475 compared to standard of care (SOC…
To compare pembrolizumab plus gemcitabine plus cisplatin to placebo plus gemcitabine plus cisplatin with respect to overall survival (OS) and progression free survival (PFS).
To determine the activity and safety of nivolumab (as monotherapy or in combination with other immunomodulatory treatments) after different immune response induction treatments in TNBC patients with metastatic disease.